Replies to post #127348 on Biotech Values

[biomaven0]

gets approved for third-line therapy, would reimbursement issues prevent doctors from using Ponatinib in first-line or second-line, if they chose to do so?

Typically not, although some insurers require "step-therapy" for conditions like CML - you have to progress through the required list of approved drugs in some sort of order.

Once Gleevec goes generic, things might become tougher. Certainly there will be significant pressure to use Gleevec until it fails.

Peter